NASDAQ:PRLD

Prelude Therapeutics Stock Forecast, Price & News

$31.73

-0.31 (-0.97 %)

(As of 08/2/2021 12:00 AM ET)

Add

Compare

Today's Range

$31.34

▼

$32.54

50-Day Range

$25.78

▼

$34.78

52-Week Range

$23.69

▼

$95.38

Volume307,253 shs

Average Volume220,391 shs

Market Capitalization$1.49 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive PRLD News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Sells $709,400.00 in Stock
July 29, 2021 | americanbankingnews.com

Prelude Therapeutics (NASDAQ:PRLD) Shares Down 4.2%
July 28, 2021 | americanbankingnews.com

Why BofA Is Turning Bullish On Prelude Therapeutics
July 27, 2021 | markets.businessinsider.com

Prelude Therapeutics (NASDAQ:PRLD) Shares Gap Up to $33.33
July 27, 2021 | americanbankingnews.com

Prelude Therapeutics (NASDAQ:PRLD) Upgraded at Bank of America
July 27, 2021 | americanbankingnews.com

Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 4.8%
July 23, 2021 | americanbankingnews.com

Prelude Therapeutics (NASDAQ:PRLD) Shares Down 5.2%
July 21, 2021 | americanbankingnews.com

Prelude Therapeutics (NASDAQ:PRLD) Shares Gap Down to $31.37
July 20, 2021 | americanbankingnews.com

Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors
July 19, 2021 | finance.yahoo.com

Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 4.4%
July 15, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRLD
Previous Symbol
CUSIPN/A
CIK1678660
Webwww.preludetx.com
Phone302-644-5427
Employees105
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.86 per share
Price / Book6.53

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares46,958,000
Market Cap$1.49 billion
Next Earnings Date8/10/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.37 out of 5 stars

Medical Sector

178th out of 2,226 stocks

Pharmaceutical Preparations Industry

87th out of 870 stocks

3.3 Analyst's Opinion

Consensus Rating
Prelude Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $59.80, Prelude Therapeutics has a forecasted upside of 88.5% from its current price of $31.73.
Amount of Analyst Coverage
Prelude Therapeutics has only been the subject of 1 research reports in the past 90 days.

4.4 Community Rank

Outperform Votes
Prelude Therapeutics has received 12 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Prelude Therapeutics has received 6 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Prelude Therapeutics has received 66.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Prelude Therapeutics and other stocks. Vote “Outperform” if you believe PRLD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRLD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Prelude Therapeutics does not currently pay a dividend.
Dividend Growth
Prelude Therapeutics does not have a long track record of dividend growth.

4.2 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prelude Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,903,922.00 in company stock.
Percentage Held by Insiders
77.38% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
69.26% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Prelude Therapeutics are expected to decrease in the coming year, from ($2.12) to ($3.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prelude Therapeutics is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prelude Therapeutics is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Prelude Therapeutics has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Prelude Therapeutics (NASDAQ:PRLD) Frequently Asked Questions

Is Prelude Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Prelude Therapeutics stock.
View analyst ratings for Prelude Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Prelude Therapeutics?

Wall Street analysts have given Prelude Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Prelude Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Prelude Therapeutics?

Prelude Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 3,400,000 shares, an increase of 32.3% from the June 15th total of 2,570,000 shares. Based on an average daily volume of 211,100 shares, the short-interest ratio is presently 16.1 days. Approximately 7.9% of the company's stock are sold short.
View Prelude Therapeutics' Short Interest.

When is Prelude Therapeutics' next earnings date?

Prelude Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Prelude Therapeutics.

How were Prelude Therapeutics' earnings last quarter?

Prelude Therapeutics Incorporated (NASDAQ:PRLD) posted its quarterly earnings results on Tuesday, May, 11th. The company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.05.
View Prelude Therapeutics' earnings history.

What price target have analysts set for PRLD?

5 equities research analysts have issued 12 month price objectives for Prelude Therapeutics' stock. Their forecasts range from $37.00 to $80.00. On average, they anticipate Prelude Therapeutics' share price to reach $59.80 in the next year. This suggests a possible upside of 88.5% from the stock's current price.
View analysts' price targets for Prelude Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Prelude Therapeutics' key executives?

Prelude Therapeutics' management team includes the following people:

Dr. Krishna Vaddi D.V.M., Ph.D., Founder, CEO & Director (Age 55, Pay $645.73k)
Mr. Christopher Pierce M.B.A., Exec. VP & Chief of Bus. Operations (Age 41, Pay $336.37k)
Dr. Deborah Morosini, Exec. VP & Chief of Clinical Affairs (Age 62, Pay $326.81k)
Mr. Brian D. Piper M.B.A., MBA, Chief Financial Officer (Age 49)
Dr. Peggy A. Scherle Ph.D., Chief Scientific Officer (Age 60)
Dr. David J. Mauro, Chief Medical Officer (Age 56)
Dr. Andrew P. Combs Ph.D., Exec. VP & Head of Chemistry (Age 55)

Who are some of Prelude Therapeutics' key competitors?

Some companies that are related to Prelude Therapeutics include Sarepta Therapeutics (SRPT), Ultragenyx Pharmaceutical (RARE), Ionis Pharmaceuticals (IONS), Apellis Pharmaceuticals (APLS), Blueprint Medicines (BPMC), Schrödinger (SDGR), Arvinas (ARVN), Reata Pharmaceuticals (RETA), Hypera (HYPMY), Alkermes (ALKS), Allakos (ALLK), Galapagos (GLPG), TG Therapeutics (TGTX), Arena Pharmaceuticals (ARNA) and Lyell Immunopharma (LYEL).
View all of PRLD's competitors.

When did Prelude Therapeutics IPO?

(PRLD) raised $149 million in an initial public offering on Friday, September 25th 2020. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO.

What is Prelude Therapeutics' stock symbol?

Prelude Therapeutics trades on the NASDAQ under the ticker symbol "PRLD."

Who are Prelude Therapeutics' major shareholders?

Prelude Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (0.04%). Company insiders that own Prelude Therapeutics stock include Brian Piper, Christopher Pierce, David J Mauro and Peggy Scherle.
View institutional ownership trends for Prelude Therapeutics.

Which major investors are buying Prelude Therapeutics stock?

PRLD stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P..
View insider buying and selling activity for Prelude Therapeutics or or view top insider-buying stocks.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prelude Therapeutics' stock price today?

One share of PRLD stock can currently be purchased for approximately $31.73.

How much money does Prelude Therapeutics make?

Prelude Therapeutics has a market capitalization of $1.49 billion. The company earns $-56,930,000.00 in net income (profit) each year or ($4.56) on an earnings per share basis.

How many employees does Prelude Therapeutics have?

Prelude Therapeutics employs 105 workers across the globe.

What is Prelude Therapeutics' official website?

The official website for Prelude Therapeutics is www.preludetx.com.

How can I contact Prelude Therapeutics?

The company can be reached via phone at 302-644-5427 or via email at [email protected]

This page was last updated on 8/2/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here